Trexquant Investment LP trimmed its holdings in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 82.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,523 shares of the biopharmaceutical company’s stock after selling 16,682 shares during the period. Trexquant Investment LP’s holdings in SAGE Therapeutics were worth $498,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Flinton Capital Management LLC lifted its position in SAGE Therapeutics by 1,900.0% during the second quarter. Flinton Capital Management LLC now owns 680 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 646 shares in the last quarter. US Bancorp DE raised its stake in shares of SAGE Therapeutics by 5,593.3% during the second quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 839 shares during the period. Creative Planning purchased a new stake in shares of SAGE Therapeutics during the second quarter valued at approximately $210,000. Tiverton Asset Management LLC purchased a new stake in shares of SAGE Therapeutics during the second quarter valued at approximately $229,000. Finally, Opera Trading Capital purchased a new stake in shares of SAGE Therapeutics during the third quarter valued at approximately $233,000.

Shares of NASDAQ:SAGE opened at $108.47 on Wednesday. The firm has a market capitalization of $5.41 billion, a P/E ratio of -15.30 and a beta of 2.72. SAGE Therapeutics Inc has a 12-month low of $88.03 and a 12-month high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.41) by ($0.22). During the same period last year, the company posted ($1.97) EPS. On average, analysts expect that SAGE Therapeutics Inc will post -7.58 EPS for the current year.

A number of research firms have recently issued reports on SAGE. Oppenheimer began coverage on shares of SAGE Therapeutics in a research note on Wednesday, October 10th. They set a “buy” rating and a $170.00 price objective on the stock. Royal Bank of Canada lifted their price objective on shares of SAGE Therapeutics from $259.00 to $261.00 and gave the company an “outperform” rating in a research note on Monday, November 5th. Canaccord Genuity set a $220.00 price objective on shares of SAGE Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 8th. Morgan Stanley lifted their price objective on shares of SAGE Therapeutics from $228.00 to $230.00 and gave the company an “overweight” rating in a research note on Thursday, October 11th. Finally, BidaskClub upgraded shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 30th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $204.14.

COPYRIGHT VIOLATION WARNING: “Trexquant Investment LP Sells 16,682 Shares of SAGE Therapeutics Inc (SAGE)” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/trexquant-investment-lp-sells-16682-shares-of-sage-therapeutics-inc-sage/2662770.html.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Further Reading: What is a Derivative?

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.